• Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Amanda E Clarke, Chien-Ching Hung, Jürgen K Rockstroh, Pierre-Marie Girard, Jörg Sievers, Choy Man, Alexander Currie, Mark Underwood, Allan R Tenorio, Keith Pappa, Brian Wynne, Anna Fettiplace, Martin Gartland, Michael Aboud, Kimberly Smith, and the GEMINI Study Team Read More
  • SWORD Studies

    Josep M Llibre, Chien-Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre-Marie Girard, Lesley P Kahl, Elizabeth A Blair, Kostas Angelis, Brian Wynne, Kati Vandermeulen, Mark Underwood, Kim Smith, Martin Gartland, Michael Aboud January 5, 2018 Read More
  • SAILING study (48-week data)

    Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

    Cahn P, Pozniak AL, Mingrone H, et al, on behalf of the extended SAILING Study Team Lancet 2013; 382: 700–708. Read More
  • SINGLE study (144-week data)

    Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naïve Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial

    Sharon Walmsley, MD, Axel Baumgarten, MD, Juan Berenguer, MD, Franco Felizarta, MD, Eric Florence, MD, Marie-Aude Khuong-Josses, MD, J. Michael Kilby, MD, Thomas Lutz, MD, Daniel Podzamczer, MD, Joaquin Portilla, MD, Norman Roth, MD, Deborah Wong, MSc, Catherine Granier, DESS, Brian Wynne, MD and Keith Pappa, PharmD J Acquir Immune Defic Syndr 2015;70:515-519 Read More

HIV Guidelines

Recommended guideline options for the treatment of HIV

UK/DTGP/0037/16(10) | November 2018